This procedure is a flow cytometric assay that uses whole blood to screen for abnormalities in the expression of CD40L and binding of CD40-Ig FP (Fusion Protein) on the surface of in vitro activated CD4+ T cells. It has also been observed that both gene and surface expression of CD40L by activated T cells is depressed in a subgroup of common variable immunodeficiency.
This flow cytometry assay is intended to be used as a screening test. Screening tests are not 100% sensitive nor specific, and a normal result should not preclude molecular sequencing if a patient’s clinical presentation suggests that the probability of a diagnosis is high.
Common Indications
CVID, X-HIGM
CPT Codes
88184, 88185 x 5, 88187
Collection
Notes
This test is New York DOH approved.
Collect
3 mL blood in Sodium Heparin
Minimum Collection Volume
2 mL Sodium Heparin
Unacceptable Conditions
Frozen, clotted, hemolyzed or centrifuged specimens. Specimen collected in an unacceptable anticoagulant.
Storage/Transport Temperature
AMBIENT
Specimen Preparation
Keep specimen as whole blood at room temperature. Specimen must be received in lab within 24 hours of collection.
This procedure is a flow cytometric assay that uses whole blood to screen for abnormalities in the expression of CD40L and binding of CD40-Ig FP (Fusion Protein) on the surface of in vitro activated CD4+ T cells. It has also been observed that both gene and surface expression of CD40L by activated T cells is depressed in a subgroup of common variable immunodeficiency.
This flow cytometry assay is intended to be used as a screening test. Screening tests are not 100% sensitive nor specific, and a normal result should not preclude molecular sequencing if a patient’s clinical presentation suggests that the probability of a diagnosis is high.
